Scientists have engineered immune cells to be more effective at fighting T-cell leukemia. They modified these cells to lack a protein called CD147, which altered their behavior and showed potential for a new approach to therapy. Additionally, a special antibody was developed that, in conjunction with the engineered cells, can precisely target and destroy leukemia cells while leaving healthy cells unharmed. This combination offers a promising new strategy for treating this challenging cancer.
เงินทุน
Chiang Mai University, the National Research Council of Thailand (NRCT), and the Faculty of Associated Medical Sciences, Chiang Mai University.
กระดาษต้นฉบับ
ชื่อบทความต้นฉบับ: Engineered CD147-Deficient THP-1 Impairs Monocytic Myeloid-Derived Suppressor Cell Differentiation but Maintains Antibody-Dependent Cellular Phagocytosis Function for Jurkat T-ALL Cells with Humanized Anti-CD147 Antibody.
วารสาร: International Journal of Molecular Sciences
ดอย: https://doi.org/10.3390/ijms25126626